/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Immix Biopharma Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.19 0.0453(4.53%) IMMX at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 3.78
Highest Today 4.17
Today’s Open 3.955
Prev. Close 3.97
52 Week High 4.60
52 Week Low 1.34
Day’s Range: Low 3.78 High 4.17
52-Week Range: Low 1.34 High 4.60
1 day return -
1 Week return -3.16
1 month return +24.02
3 month return +87.72
6 month return +96.66
1 year return +77.25
3 year return +250.0
5 year return -
10 year return -

Institutional Holdings

Bleichroeder LP 2.95

Vanguard Group Inc 2.42

Vanguard Total Stock Mkt Idx Inv 1.69

Geode Capital Management, LLC 0.56

Vanguard Institutional Extnd Mkt Idx Tr 0.47

Morgan Stanley - Brokerage Accounts 0.43

Northern Trust Corp 0.33

Fidelity Extended Market Index 0.27

Susquehanna International Group, LLP 0.18

State Street Corp 0.15

BlackRock Inc 0.14

Timber Point Global Allocations Instl 0.14

iShares Micro-Cap ETF 0.13

Private Advisor Group, LLC 0.11

Tocqueville Asset Management L.P. 0.10

Velan Capital Investment Management LP 0.09

TRITONPOINT WEALTH LLC 0.09

Fidelity Total Market Index 0.08

Fidelity Series Total Market Index 0.07

Northern Trust Extended Eq Market Idx 0.07

NT Ext Equity Mkt Idx Fd - L 0.07

Spartan Extended Market Index Pool F 0.07

NT Ext Equity Mkt Idx Fd - NL 0.06

Virtu Financial LLC 0.06

SBI Securities Co Ltd 0.06

Northern Small Cap Core I 0.06

Commonwealth Equity Services Inc 0.06

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.05

UBS Group AG 0.05

Fidelity Nasdaq Composite Index 0.05

The Colony Group LLC 0.04

Royal Bank of Canada 0.04

Spartan Total Market Index Pool G 0.03

NT Quality SCC US Fund - L 0.03

NT Quality Small Cap Core 0.03

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.02

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

Shaker Financial Discount Capture 0.02

Wells Fargo & Co 0.00

Bank of America Corp 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 133.30 M

PB Ratio 16.4132

PE Ratio 0.0

Enterprise Value 120.81 M

Total Assets 22.95 M

Volume 485072

Company Financials

Annual Revenue FY23:0 0.0M, FY22:-89517000 -89.5M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:-89517000 -89.5M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-14136381 -14.1M, FY22:-8229713 -8.2M, FY21:-24383879 -24.4M, FY20:-1147863 -1.1M, FY19:-972811 -1.0M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-79835 -0.1M, Q1/2025:-59180 -0.1M, Q3/2024:null 0.0M, Q2/2024:-24295 -0.0M

Quarterly Net worth Q3/2025:-7585692 -7.6M, Q2/2025:-6622563 -6.6M, Q1/2025:-4542528 -4.5M, Q3/2024:-7149395 -7.1M, Q2/2024:-4392936 -4.4M

Fund house & investment objective

Company Information Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Organisation Biotechnology

Employees 18

Industry Biotechnology

CEO Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow